Back to Journals » Oncolytic Virotherapy » Volume 5

Oncolytic Virotherapy


Archive: Volume 5, 2016

CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter

Bhatia S, O’Bryan SM, Rivera AA, Curiel DT, Mathis JM

Oncolytic Virotherapy 2016, 5:99-113

Published Date: 11 November 2016

Oncolytic virotherapy for pediatric malignancies: future prospects

Waters AM, Friedman GK, Ring EK, Beierle EA

Oncolytic Virotherapy 2016, 5:73-80

Published Date: 11 August 2016

Myxoma virus therapy of human embryonal rhabdomyosarcoma in a nude mouse model

Kinn VG, Hilgenberg VA, MacNeill AL

Oncolytic Virotherapy 2016, 5:59-71

Published Date: 8 August 2016

Oncolytic adenovirus-mediated therapy for prostate cancer

Sweeney K, Halldén G

Oncolytic Virotherapy 2016, 5:45-57

Published Date: 14 July 2016

Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy

Guan M, Ma Y, Shah SR, Romano G

Oncolytic Virotherapy 2016, 5:35-43

Published Date: 21 June 2016

Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy

Al-Shammari AM, Rameez H, Al-Taee MF

Oncolytic Virotherapy 2016, 5:27-34

Published Date: 20 April 2016

High-throughput screening to enhance oncolytic virus immunotherapy

Allan KJ, Stojdl DF, Swift SL

Oncolytic Virotherapy 2016, 5:15-25

Published Date: 5 April 2016

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances

Simpson GR, Relph K, Harrington K, Melcher A, Pandha H

Oncolytic Virotherapy 2016, 5:1-13

Published Date: 6 January 2016